Tech Company Financing Transactions

Cyteir Therapeutics Funding Round

Cyteir Therapeutics closed a $40.2 million Series B funding round on 10/16/2019. Investors included Novo Ventures, Celgene and DROIA.

Transaction Overview

Company Name
Cyteir Therapeutics
Announced On
10/16/2019
Transaction Type
Venture Equity
Amount
$40,200,000
Round
Series B
Investors

Novo Ventures (Lead Investor)

Celgene (Markus Renschler)

DROIA (Bart Hooland)

Lightstone Ventures (Jean George)

Osage Partners

Venrock (Racquel Bracken)

Proceeds Purpose
The additional funding will be used to expand the clinical investigation of Cyteir's first-in-class RAD51 inhibitor and lead compound, CYT-0851, and to identify new targets using the company's novel gain-of-function synthetic lethality screening platform.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
128 Spring St. Building A 510
Lexington, MA 02421
USA
Phone
(857) 285-4140
Website
www.cyteir.com
Email Address
[email protected]
Overview
DNA damage and genomic instability are hallmarks of cancer and autoimmune diseases. This makes the disease-causing cells highly sensitive to drugs that target specific DNA repair factors. This is termed synthetic lethality.
Profile
Cyteir Therapeutics LinkedIn Company Profile
Social Media
Cyteir Therapeutics Company Twitter Account
Company News
Cyteir Therapeutics News
Facebook
Cyteir Therapeutics on Facebook
YouTube
Cyteir Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Markus Renschler
  Markus Renschler LinkedIn Profile  Markus Renschler Twitter Account  Markus Renschler News  Markus Renschler on Facebook
Chief Scientific Officer
Paul Secrist
  Paul Secrist LinkedIn Profile  Paul Secrist Twitter Account  Paul Secrist News  Paul Secrist on Facebook
Vice President
Jean-Marc Lapierre
  Jean-Marc Lapierre LinkedIn Profile  Jean-Marc Lapierre Twitter Account  Jean-Marc Lapierre News  Jean-Marc Lapierre on Facebook
Vice President
Thomas O'Shea
  Thomas O'Shea LinkedIn Profile  Thomas O'Shea Twitter Account  Thomas O'Shea News  Thomas O'Shea on Facebook
VP - Bus. Development
Andrew Gengos
  Andrew Gengos LinkedIn Profile  Andrew Gengos Twitter Account  Andrew Gengos News  Andrew Gengos on Facebook
VP - Operations
Susan Doleman
  Susan Doleman LinkedIn Profile  Susan Doleman Twitter Account  Susan Doleman News  Susan Doleman on Facebook
VP - R & D
Judson Englert
  Judson Englert LinkedIn Profile  Judson Englert Twitter Account  Judson Englert News  Judson Englert on Facebook
VP - R & D
Barbara Wan
  Barbara Wan LinkedIn Profile  Barbara Wan Twitter Account  Barbara Wan News  Barbara Wan on Facebook

 

 

Browse more venture capital transactions:

Prev: 10/16/2019: Provivi venture capital transaction
Next: 10/16/2019: Redesign Science venture capital transaction

 

Share this article

 

News on VC Transactions

Our team works diligently to document every notable VC transaction. All VC database entries on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.